ICD-10 D47.1 is officially defined as "Chronic myeloproliferative disease." code D47.1 is referenced in 12 tracked payer policy changes from Independence Blue Cross, Excellus BlueCross BlueShield, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code D47.1 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Independence Blue Cross updated MA08.011i to align with FDA labeling and NCCN guidelines for Erythropoiesis Stimulating Agents (ESAs). The policy revises medical necessity criteria for myelodysplastic syndrome, cancer-related anemia, HIV/AIDS, and pediatric chronic kidney disease, and adds 18 new ICD-10 diagnosis codes effective June 29, 2026.
Excellus medical policy 7.02.02 sets when allogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered medically appropriate. It applies when the candidate meets the transplanting institution's selection criteria, the multidisciplinary team evaluates the individual and recommends treatment, and the individual is treated for one of the listed indications. The listed indications include acute and chronic leukemias, non-Hodgkin lymphoma, myelodysplastic diseases at intermediate or high risk, sickle cell anemia under stated criteria, transfusion-dependent thalassemia, bone marrow failure syndromes, severe combined immunodeficiency, hemophagocytic disorders, several storage and leukodystrophy disorders, and certain skeletal and metabolic bone disorders. Allo-HSCT is considered investigational for all other indications. The February 19, 2026 revision simplified the criteria to the indication level, removed the investigational indications list and added HCPCS code S2142.
Independence Blue Cross updated ESA policy 08.00.75q to 08.00.75r effective 11/17/2025, revising coverage criteria for Myelodysplastic Syndrome and Cancer-Related Anemia based on FDA labeling and NCCN guidelines. Seven new ICD-10 diagnosis codes were added to expand eligible patient populations, including acute panmyelosis with myelofibrosis variants, myelodysplastic disease, chronic myeloproliferative disease, osteomyelofibrosis, and anemia in neoplastic disease.
Aetna Clinical Policy Bulletin 1032 addresses omidubicel-onlv (Omisirge) for commercial medical plans. Aetna considers it medically necessary for one dose total in members 12 years of age and older with a hematologic malignancy who will receive umbilical cord blood transplantation with myeloablative conditioning, and for one dose total in members 6 years of age and older with severe aplastic anemia (SAA) following reduced intensity conditioning. Aetna considers all other indications experimental, investigational, or unproven.
Aetna's interferon policy covers Actimmune (interferon gamma-1b) for chronic granulomatous disease, mycosis fungoides/Sezary syndrome and severe malignant osteopetrosis, and considers all other indications experimental, investigational, or unproven. Pegasys (peginterferon alfa-2a) and Besremi (ropeginterferon alfa-2b-njft) each have their own list of covered indications, and several Besremi indications are covered only when Pegasys is unavailable. Aetna considers continuation of therapy medically necessary for members who are experiencing benefit, as evidenced by disease stability or disease improvement, and the Biojector 2000 needle-free injection system is considered a medically necessary alternative to needles for members with exacerbating-remitting MS who cannot safely self-inject due to tremors and decreased coordination.
Aetna covers Actimmune (interferon gamma-1b) for chronic granulomatous disease, severe malignant osteopetrosis, and mycosis fungoides/Sezary syndrome, and considers all other indications experimental, investigational, or unproven. Aetna covers peginterferon alfa-2a (Pegasys) for adult T-cell leukemia/lymphoma, chronic hepatitis B for up to a total of 48 weeks, chronic hepatitis C, chronic hepatitis E in liver transplant recipients who meet the ribavirin criteria, and several myeloproliferative, mastocytosis, and lymphoma indications. Ropeginterferon alfa-2b-njft (Besremi) is covered for polycythemia vera and for several other indications when peginterferon alfa-2a (Pegasys) is unavailable.
Aetna considers decitabine medically necessary for accelerated or blast phase myeloproliferative neoplasm, acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm when used with venetoclax, classic Hodgkin lymphoma when used with pembrolizumab and refractory to at least three prior lines of therapy, myelodysplastic syndromes, and myelodysplastic syndrome/myeloproliferative neoplasm overlap neoplasms. Continuation of decitabine is considered medically necessary for those indications when there is no evidence of unacceptable toxicity or disease progression on the current regimen. Aetna considers decitabine experimental, investigational, or unproven for all other indications, including colon, lung, melanoma, ovarian and other solid tumors, multiple myeloma, sickle cell disease, and use in combination with azacitidine.
Aetna's clinical policy bulletin for omidubicel-onlv (Omisirge) applies to commercial medical plans and states that precertification is required of all Aetna participating providers and members in applicable plan designs. Aetna considers omidubicel-onlv medically necessary for one dose total in members 12 years of age and older with a hematologic malignancy who will receive umbilical cord blood transplantation, when the requested medication will be used to reduce the time to neutrophil recovery and incidence of infection and the member will receive myeloablative conditioning therapy. It is also considered medically necessary for one dose total in members 6 years of age and older with severe aplastic anemia (SAA) following reduced intensity conditioning therapy, and Aetna considers all other indications experimental, investigational, or unproven.
Aetna considers azacitidine (Vidaza or generic azacitidine) medically necessary for myelodysplastic syndromes, acute myeloid leukemia, accelerated or blast phase myeloproliferative neoplasm, blastic plasmacytoid dendritic cell neoplasm when used in combination with venetoclax, and myelodysplastic syndrome/myeloproliferative neoplasms overlap neoplasms. Peripheral T-cell lymphoma, including angioimmunoblastic T-cell lymphoma, nodal peripheral T-cell lymphoma with TFH phenotype, and follicular T-cell lymphoma, is considered medically necessary only when azacitidine is used as subsequent therapy for relapsed or refractory disease and as a single agent. All other indications are considered experimental, investigational, or unproven.
8.01.21 on allogeneic hematopoietic cell transplantation for myelodysplastic syndromes and myeloproliferative neoplasms. Myeloablative allogeneic transplant may be considered medically necessary as a treatment for these disorders, and reduced-intensity conditioning allogeneic transplant may be considered medically necessary as a risk-adapted treatment for individuals at high risk of intolerance of a myeloablative regimen. Myeloablative or reduced-intensity allogeneic transplant for cases that do not meet the policy guidelines criteria is investigational. A 07/23/2026 policy review updated the description with minor changes, left the policy statements unchanged and removed ICD-9 procedure and diagnosis codes from the code reference.
Epogen (epoetin alfa), Procrit (epoetin alfa), and Retacrit (epoetin alfa-epbx) are considered medically necessary for anemia related to zidovudine therapy in HIV-infected individuals, anemia in non-myeloid malignancies caused by concomitantly administered chemotherapy, anemia in individuals scheduled for elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, and anemia associated with chronic kidney disease. Aranesp (darbepoetin alfa) is considered medically necessary for anemia associated with chronic kidney disease, including individuals on dialysis and not on dialysis, and for anemia in non-myeloid malignancies caused by concomitantly administered chemotherapy. The 09/09/2025 revision updated the indications descriptions and added that services related to delivery or administration of a medication determined to be not medically necessary are also considered not medically necessary.
JAK2 testing may be considered medically necessary to diagnose individuals with clinical, laboratory, or pathologic findings suggesting polycythemia vera, essential thrombocythemia, or primary myelofibrosis. MPL and CALR testing may be considered medically necessary to diagnose individuals with findings suggesting essential thrombocythemia or primary myelofibrosis. JAK2, MPL, and CALR testing is considered investigational for nonclassic forms of myeloproliferative neoplasms, molecular phenotyping, and monitoring, management, or selecting treatment in myeloproliferative neoplasms.
Watch D47.1
Get one email when a payer policy names D47.1, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.